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Abstract
Osteoprotegerin (OPG) is a secreted protein and member of the Tumor Necrosis Factor (TNF) Receptor superfamily.
OPG has been well characterized as a regulator of bone metabolism which acts by blocking osteoclast maturation
and preventing bone breakdown. Given this role, early studies on OPG in breast cancer focused on the administration of
OPG in order to prevent the osteolysis observed with bone metastases. However OPG is also produced by the breast
tumor cells themselves. Research focusing on OPG produced by breast tumor cells has revealed actions of OPG which
promote tumor progression. In vitro studies into the role of OPG produced by breast tumor cells have demonstrated that
OPG can block TNF-related apoptosis inducing ligand (TRAIL)-mediated apoptosis. Furthermore, in vivo studies show that
OPG expression by breast tumors can promote tumor growth and metastasis. In addition it has been shown that OPG
stimulates endothelial cell survival and tube formation thus it may indirectly promote breast tumor progression through
impacting angiogenesis. This article will present a summary of the data concerning the tumor-promoting effects of OPG
in breast cancer.
Keywords: Osteoprotegerin, Bone, TNF-related apoptosis inducing ligand (TRAIL), Apoptosis, Angiogenesis, Metastasis
Introduction
Osteoprotegerin (OPG) is a secreted protein that acts in
the bone to block the maturation of bone resorbing
osteoclast cells and thus prevent bone breakdown [1, 2].
This physiological role led to investigation of the use of
recombinant OPG as a treatment to prevent the bone
breakdown that can be initiated when breast cancers
metastasize and grow in the bone. However primary
breast tumors also express OPG indicating the potential
for OPG to have additional roles in breast tumorigenesis
[3, 4]. Significant evidence has now accumulated from
cell culture and animal model studies indicating that
OPG can promote breast tumor growth and spread. This
review will present current work illustrating the tumor
promoting effects of OPG in breast cancer. These stud-
ies demonstrate that OPG should be considered in a
dual light in breast cancer having actions that can both
promote breast tumor progression as well as prevent
bone destruction.
Review
Identification of OPG and characterization as a mediator
of bone re-modeling
OPG was initially identified through sequence homology
to the tumor necrosis factor (TNF) receptor superfamily.
OPG contains the four cysteine-rich domain repeats
characteristic of the TNF receptor family but lacks a
transmembrane region and is therefore a secreted pro-
tein [1, 5, 2]. In addition to the cysteine-rich repeats
OPG contains two death domain homologous regions as
well as a heparin-binding site [6].
Generation of transgenic mice has allowed elucidation
of the major physiological role of OPG as a regulator of
bone metabolism. OPG over-expression results in a lack
of mature bone-resorbing osteoclasts and a pronounced
increase in bone density known as osteopetrosis [1].
Mice in which the gene for OPG has been knocked
down show the opposite phenotype – an increased num-
ber of mature osteoclasts and severe bone loss or osteo-
porosis [7, 8]. These phenotypes combined with in vitro
osteoclast maturation studies demonstrate that OPG
acts as a negative regulator of bone metabolism and
blocks osteoclast maturation [1, 2]. Subsequent studies
revealed that OPG exerts this effect by acting as a decoy
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receptor for Receptor Activator of NF-kappaB ligand
(RANKL). OPG binds to RANKL preventing its inter-
action with the receptor RANK and thus blocks stimula-
tion of osteoclast maturation [9, 10].
OPG and bone metastasis
Given the characterization of the role of OPG as a nega-
tive regulator of bone metabolism as described above,
early studies on OPG and breast cancer focused on the
bone microenvironment. Bone is the most common site
of breast cancer metastasis. Breast tumors tend to form
osteolytic metastases where the tumor is surrounded by
osteoclasts which degrade the bone tissue [11-13]. An
imbalance of the RANK/RANKL/OPG pathway has been
observed in tumors with an up-regulation of RANKL
and a down-regulation of OPG [14]. As OPG is known
to inhibit osteoclast maturation, studies have looked at
the use of recombinant OPG to prevent bone loss re-
lated to bone metastasis. Truncated forms of recombin-
ant OPG were developed containing the N-terminal
portion of the protein necessary for interaction with
RANKL fused to the Fc domain of human IgG. The Fc-
OPG construct prevented formation of osteolytic meta-
static lesions by MDA-MB-231 human breast cancer
cells in nude mice [15] and in ovariectomised nude mice
[16]. In addition, a reduction in serum markers of bone
resorption was observed in a Phase I study in which Fc-
OPG was administered to breast cancer patients [17].
Further testing of this construct was not pursued due to
concerns regarding an immune response against en-
dogenous OPG [18]. A monoclonal antibody against
RANKL, Denosumab, has instead been developed and
approved to prevent skeletal-related events and bone
loss in patients with advanced breast cancer [19]. Deno-
sumab is also being tested in a Phase III clinical trial, D-
CARE (ClinicalTrials.gov Identifier: NCT01077154), to
determine whether it can prevent breast cancer recur-
rence in the bone or other tissues in women with early-
stage breast cancer at high risk of recurrence.
These early studies focused on actions of exogenously
added, truncated OPG within the bone microenviron-
ment. However, subsequent studies that are described
below demonstrate a more extensive and complex role
for OPG in breast cancer.
OPG expression in breast cancer cells and tissue
One of the first studies to characterize OPG revealed ex-
pression in two human breast cancer cell lines – MDA-
MB-436 and MCF-7 [5]. Further studies have confirmed
the expression of OPG by breast cancer cell lines and
tissues. The MCF-7, MDA-MB-231 and T47D human
breast cancer cells lines were tested for OPG mRNA ex-
pression by RT-PCR alongside 12 primary breast tumor
samples [20]. OPG mRNA expression is up-regulated in
human breast cancer cell lines and tumor samples. The
expression pattern of OPG was examined by immuno-
histochemistry in 400 invasive breast cancer tissue sam-
ples [3]. It was found that 40 % of the invasive breast
tumors expressed OPG with expression confined to
tumor cells. This finding was validated in a recent study
where 175 patient breast tumor samples were analyzed
and it was found that 45.9 % of tumors expressed OPG
[4]. It should be noted that the expression of OPG by
tumor cells is not limited to breast cancer. Expression of
OPG has been observed in other cancer cell types in-
cluding colon, prostate and bladder cancer illustrating
the potential for a broader role in tumorigenesis [21].
While there have been no investigations focusing on
OPG in normal breast epithelium, OPG knockout mice
are able to maintain litters which would suggest that
OPG is not required for normal mammary gland devel-
opment and lactation [8]. It appears that OPG expres-
sion is associated with breast tumor formation.
Regulation of OPG expression in breast cancer
The studies described above demonstrate a basal level of
expression of OPG in breast cancer cells and tissue. Fur-
ther investigation has revealed the potential for modula-
tion of OPG expression levels within breast tumors.
Immunohistochemical staining of human breast tumor
samples showed that OPG expression correlated with
the presence of the Estrogen and Progesterone receptors
[22]. However a functional investigation of the link be-
tween the Estrogen Receptor (ER) and OPG expression
suggests a negative relationship where activation of ER
reduces OPG expression. Treatment of the ER-positive
MCF-7 breast cancer cell line with 17beta-estradiol
inhibited OPG mRNA and protein expression and this
effect was reversed by the estrogen receptor antagonist
ICI 182,780 [23]. While estrogen appears to down-
regulate OPG expression, treatment of MCF-7 and
MDA-MB-231 breast cancer cells with Interleukin-1Beta
increased OPG mRNA and protein expression [24].
Interaction between OPG and TNF-related apoptosis
inducing ligand (TRAIL)
TNF-related apoptosis inducing ligand (TRAIL) is se-
creted by normal tissues and preferentially induces apop-
tosis in tumor cells [25, 26]. The screening of OPG
protein with TNF-related ligands led to the discovery that
OPG could bind to TRAIL, preventing its interaction with
Death Receptors and blocking TRAIL-induced apoptosis
of Jurkat cells, a human T-lymphocyte cell line [27]. OPG
appears to act as a “decoy” receptor for TRAIL, preventing
interaction between TRAIL and the Death Receptors and
exerting an anti-apoptotic effect. Several studies demon-
strating the OPG-TRAIL interaction have been performed
in vitro using human breast cancer cell lines. TRAIL-
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induced apoptosis in MDA-MB-436 and MDA-MB-231
human breast cancer cells could be reduced by the
addition of recombinant OPG (10-1000 ng/ml). MDA-
MB-436 cells which had been incubated for 72 to 120 h to
allow accumulation of endogenous OPG were less suscep-
tible to TRAIL-induced apoptosis. This effect could be re-
versed by the addition of excess RANKL to compete for
OPG binding [3]. This anti-apoptotic effect of OPG was
confirmed through the use of OPG siRNA. MDA-MB-231
cells treated with OPG siRNA to knock down OPG ex-
pression had a higher rate of apoptosis when treated with
TRAIL as compared to control cells [24].
While in vitro studies clearly demonstrate effects of
the OPG-TRAIL interaction, the relevance of this inter-
action for breast cancer cells has yet to be demonstrated
in vivo. MDA-MB-231 human breast cancer cells were
transfected to over-express full length OPG. Despite
showing a significant increase in OPG expression along
with a reduced sensitivity to TRAIL-mediated apoptosis
in vitro, there was a lack of effect in vivo. Two weeks
after intra-tibial injection in mice of cells the anti-tumor
effect observed with TRAIL treatment was identical be-
tween empty vector and OPG over-expressing human
breast tumor cells [28].
The role of OPG produced by breast cancer cells may
be more complex in vivo due to simultaneous presence
of TRAIL and RANKL. An in vitro binding study dem-
onstrated that OPG binds TRAIL and RANKL with
equal affinity [29]. However the effect of OPG on
TRAIL-mediated apoptosis in human breast cancer cells
can be reversed by the addition of excess RANKL [3,
24]. This presents a potential mechanism whereby OPG
could be prevented from impacting TRAIL due to high
RANKL levels in the bone microenvironment. The out-
come of OPG signaling in the presence of biologically
relevant concentrations of both ligands remains to be
determined.
Tumor promoting role of OPG in breast cancer
There are now a number of in vivo studies that indicate
tumor-promoting effects of OPG on breast cancer cells,
potentially via TRAIL-independent mechanisms as de-
scribed below. MCF-7 human breast cancer cells were
engineered to express Parathyroid Hormone allowing
them to form osteolytic metastases after intra-tibial in-
jection in nude mice. Administration of truncated
recombinant Fc-OPG reduced bone destruction in
agreement with previous studies. In contrast, when the
MCF-7 cells were transfected to over-express full length
OPG and injected into mice tibias there was an increase
in osteolysis. The intra-tibial tumors from the cells over-
expressing OPG had an increase in cells staining positive
for the proliferation marker Ki67. These MCF7 cells
over-expressing OPG produced larger tumors compared
to control cells after injection into the mammary fat pad
although in this context there was no difference in Ki67
staining. The MCF-7 cells over-expressing OPG did not
show any alteration in sensitivity to TRAIL treatment in
vitro, suggesting that there must be additional mecha-
nisms whereby OPG can have a tumor-promoting effect
[30]. The contrasting results in this study may be related
to whether OPG is in the truncated or full length form
or whether it is exogenously added or produced by
breast cancer cells. In a subsequent study MDA-MB-435
human breast cancer cells were treated with a condi-
tional replicating adenovirus to express the truncated
OPG-Fc protein. These cells showed a reduction in bone
tumor formation and decrease in osteoclast numbers
compared with control adenovirus cells suggesting that
production of protein from tumor cells themselves can
still have a protective effect in the bone [31]. However
given the controversy surrounding the origin of the
MDA-MB-435 cell line, these results may not represent
a breast cancer specific effect [32].
Another in vivo study suggests that the tumor-
promoting effects of the Estrogen-Related-Receptor-
Alpha (ERRα) in breast cancer may be mediated in part
via OPG. ERRα expression in bone metastasizing MDA-
MB-231 human breast cancer cell derivatives led to an
increased expression of OPG. In agreement with this ex-
perimental observation, the analysis of 251 patient sam-
ples showed that OPG levels were significantly higher in
ERRα-positive tumors compared with ERRα-negative tu-
mors. High ERRα and high OPG expression in breast
tumor tissue from patients is associated with a greater
increase in risk of recurrence than high expression of
ERRα only. An increase in tumor growth was observed
when the ERRα expressing cells were implanted in the
mouse mammary fat pad however a reduction in
osteolysis was observed when these cells formed bone
metastases after intravenous injection in mice [33].
Therefore an increase in OPG expression by breast can-
cer cells may contribute to tumor growth at the primary
tumor site while inhibiting the destruction and conse-
quent growth in the bone.
This possibility that OPG can protect the bone micro-
environment from tumor growth while promoting
growth in other tissues is also evident in a recent study.
MDA-MB-231 human breast cancer cells were stably
transfected to express OPG and injected into the tibias
of nude mice. Over-expression of OPG by injected
breast cancer cells protected bone from destruction and
inhibited growth of the tumors within the bone. How-
ever breast cancer cells over-expressing OPG persisted
to grow in the space outside of the bone. In addition,
OPG over-expressing breast tumor cells injected into
the bone had an increased tendency to metastasize to
lungs [34].
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Despite the accumulating evidence that OPG pro-
duced by breast cancer cells may promote tumor growth
in sites outside of the bone microenvironment, the
mechanism behind this effect is unclear. We have re-
cently performed a study using MDA-MB-231 human
breast cancer cells transfected with sh- or siRNA to
knock down OPG in a chick embryo in vivo model of
breast cancer metastasis. Knockdown of OPG expression
reduced metastasis formation in chick tissues both from
a primary tumor and after direct introduction of cells by
intravenous injection. Our in vitro mechanistic studies
show that OPG knockdown cells express lower levels of
Matrix Metalloproteinase-2 and have a reduced ability
to invade through a collagen matrix. This would suggest
that OPG can exert an autocrine effect and promote
breast cancer cell invasion and metastasis [35].
The findings of these in vivo studies suggest that while
the interaction between OPG and the bone microenvir-
onment can lead to an inhibition of bone tumor growth,
OPG can promote breast tumor formation and growth
at other sites.
OPG and endothelial cells
While OPG produced by breast cancer cells may exert
effects directly on breast tumor cells it appears that
OPG’s interaction with other cells in the tumor micro-
environment may also promote breast tumorigenesis. In
particular, several studies have reported an impact of
OPG on endothelial cells suggesting the potential role of
OPG to regulate angiogenesis.
Human umbilical vein endothelial cells (HUVECs)
and Human Dermal Microvascular Endothelial cells
(HuDMECs) both express OPG. Treatment of endothe-
lial cells with recombinant OPG (100 ng/ml) promotes
cell survival and formation of cord-like structures. Ana-
lysis of human breast tumor tissues showed that OPG
is expressed by endothelial cells in breast tumor tissue
but not in normal surrounding tissue. There is a strong
positive correlation between endothelial OPG expres-
sion and tumor grade, and a strong negative correlation
between endothelial OPG expression and ER expression
[36]. Furthermore, while endothelial cells are not sensitive
to TRAIL-mediated apoptosis, conditioned medium from
endothelial cells protected MDA-MB-436 human breast
cancer cells from TRAIL. This effect was lost when OPG
was removed from the conditioned medium with antibody
treatment. This would suggest that OPG from endothelial
cells can promote breast cancer cell survival. A subse-
quent study further demonstrated the crosstalk between
breast tumor and endothelial cells related to OPG. T47D
human breast cancer cells were co-cultured directly with
HuDMECs for 72 h. There was an increase in OPG pro-
tein expression in the co-culture supernatant as compared
with HuDMECs cultured alone. Isolation of each cell type
and real-time quantitative PCR showed the co-culture
stimulated the expression of OPG mRNA in the HuD-
MECs but not in the T47D. This contact mediated induc-
tion of OPG expression in HuDMECs by the breast
cancer cells was prevented by the presence of an Integrin
αvβ3 antibody in the co-culture medium [37]. This would
suggest that Integrin αvβ3 signaling can promote OPG
expression. This study also demonstrated that OPG
(10 ng/ml) promoted tube formation by HuDMECs
confirming the potential for OPG to exert pro-
angiogenic effects.
Several studies have investigated the mechanism
whereby OPG could promote angiogenic behavior of
endothelial cells. HuDMECs treated with OPG were
elongated with extensive actin networks compared to
untreated cells. OPG (0.5-2ug/ml) led to cytoskeletal
reorganization and cell spreading; this may be mediated
by Focal Adhesion Kinase (FAK) as phosphorylation of
FAK (Y397) was induced by treatment with OPG. OPG-
mediated HuDMECs proliferation was blocked by the
Erk 1/2 inhibitors U0126 and PD98059 while OPG-
induced cell migration and cord-like structure formation
was blocked by the Src inhibitor PP1 [38]. The ability of
OPG to impact these cell signaling pathways associated
with adhesion, migration and proliferation was con-
firmed in a later study performed with endothelial col-
ony forming cells and HUVECs. OPG treatment (0.4nM)
of endothelial cells led to a transient increase in adhe-
sion associated with phosphorylation of FAK. OPG also
promoted phosphorylation of Erk1/2 and Akt [39].
Treatment of the cells with enzymes that degraded hep-
arin and chondroitin sulphate led to a reduction in
OPG-stimulated migration and chemotaxis hinting that
the heparin binding domain of OPG may be involved.
However the impact of OPG on migration, chemotaxis
and tubulogenesis was maintained when a truncated
form of OPG (1–194) was used indicating the heparin
binding domain was not necessary for pro-angiogenic
effects.
The cumulative findings of these endothelial cell stud-
ies demonstrate the potential for OPG to exert tumor-
promoting effects by stimulating angiogenesis in
addition to the direct effects of OPG on breast cancer
cells.
OPG expression and breast cancer prognosis
A few studies have investigated links between OPG and
breast cancer prognosis although conflicting findings
have been reported. Real-time quantitative PCR was
used to analyze the expression of OPG mRNA in 127
primary human breast cancer tissues. It was found pa-
tients with higher expression levels of OPG had signifi-
cantly poorer overall survival as compared with patients
who had lower OPG expression levels [40]. However, in
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a subsequent study where 175 human breast tumor sam-
ples were analyzed, no link was found between OPG ex-
pression and skeletal disease-free survival, disease-free
survival or overall survival [4]. Another study which ana-
lyzed publicly available microarray data for 295 breast
cancer patients reported that high expression of OPG
correlated with longer overall and disease free survival
[41]. It is possible that variation in findings relates to dif-
fering effects of OPG dependent on breast cancer sub-
type. An analysis of publicly available microarray data
looking at OPG in relation to human breast cancer sub-
type found that expression of OPG correlates with a bet-
ter prognosis in ER positive breast cancer while a
statistically significant difference was not observed in ER
negative breast cancer [42]. Interestingly, among the tu-
mors that expressed high levels of OPG there was a
lower fraction of ER positive cases and a higher fraction
of triple negative breast cancers. In agreement with this,
we have analyzed OPG mRNA expression in publicly
available microarray data for human breast cancer cell
lines and found that cell lines from the basal subtype
have higher levels of OPG expression than luminal sub-
type cells [35]. Further investigation is required to deter-
mine the links between OPG expression, prognosis and
breast cancer subtype.
OPG gene amplification and polymorphisms
In addition to the expression of OPG, changes in the
OPG gene have been reported in breast cancer. We
analyzed the TCGA-2013 human breast invasive carcin-
oma data set, through the cBioPortal website, and found
that OPG gene copy gain occurred in 182 out of 934 tu-
mors in the set (19.4 %). The presence of an OPG copy
number gain is a significant predictor of decreased over-
all survival in this cohort [35]. The occurrence of single
nucleotide polymorphisms (SNPs) in the OPG gene in
association with breast cancer has been examined. In
one study, it has been reported that breast cancer pa-
tients were more likely to have the minor allele C geno-
type for the OPG SNP rs3102735 as compared to
healthy controls [43]. The presence of this variant was
associated with a 1.5-fold increased risk of breast cancer.
Breast cancer patients with invasive tumors were more
likely to have the major allele G associated with the
OPG SNP rs2073618 as compared with patients with
non-invasive tumors. Another study reported the C allele
of the OPG SNP rs2073618 and T allele of the OPG SNP
rs2073617 occurred more frequently in breast cancer pa-
tients [44]. The impact of these polymorphisms on OPG
expression or function in breast cancer requires further
investigation.
Conclusions
Since its initial discovery and characterization, evidence
has been accumulating that OPG plays a role in breast
tumorigenesis. The reported actions of OPG in breast
cancer are summarized in Fig. 1. It appears that the ef-
fects of OPG in breast cancer may vary depending on
Fig. 1 Summary of reported sources and effects of OPG in breast cancer. OPG is produced by bone cells, endothelial cells and breast tumor cells.
OPG can exert tumor promoting effects on the primary breast tumor through blocking the action of TRAIL and through direct effects on tumor
cells. OPG can promote growth of endothelial cells and tubule formation. OPG promotes formation of metastatic tumors at sites out with bone.
OPG production in the bone microenvironment can block the bone destruction associated with growth of metastatic breast tumors
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site of action. OPG is present in the bone during breast
tumor metastasis and OPG is also expressed by breast
tumor cells and endothelial cells within breast tumors.
In the bone microenvironment OPG’s interaction with
bone cells can prevent the osteolysis (bone breakdown)
associated with breast cancer metastases. However the
interaction of OPG with breast cancer cells themselves
can lead to tumor growth and spread. This may occur
via the ability of OPG to block the induction of apop-
tosis by TRAIL or through other novel mechanisms.
Furthermore, the interaction between RANKL and OPG
remains to be investigated in the context of the primary
breast tumor. OPG further extends its impact in the
breast tumor microenvironment via stimulating growth
of endothelial cells and promotion of tubule formation.
The effects of OPG may be related to source of OPG
with different outcomes resulting from exogenous
addition versus production by breast cancer cells them-
selves. Differing effects have also been observed with
truncated OPG versus full length OPG suggesting that
the different domains within the protein mediate mul-
tiple types of actions within the breast tumor.
While OPG clearly has potential to modulate breast
tumor growth and progression, further investigation is
required to fully determine the mechanism of effect and
overall outcomes of the different types of interactions.
The data available currently would suggest that OPG
can no longer be considered solely in the bone micro-
environment in breast cancer and caution must be exer-
cised in the development of systemic treatment strategies
aimed at increasing OPG levels. Localized delivery of
OPG to the bone may be more appropriate to prevent
osteolysis associated with metastatic breast cancer. Add-
itional studies are required to determine whether strat-
egies to block OPG signaling would be effective in
blocking the growth and progression of primary breast
tumors.
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